How it works

From question to source-verified synthesis

RAGMD is a clinical evidence engine — not a generic medical chatbot. Evidence first. AI second.

  1. 1

    Ask a clinical question

    RAGMD identifies the population, intervention, outcomes, and type of evidence needed.

  2. 2

    Find the evidence

    RAGMD searches its evidence library and expands to current literature when needed.

  3. 3

    Determine what matters

    Studies are evaluated for relevance, design, directness, quality, precision, and applicability.

  4. 4

    Look for disagreement

    RAGMD identifies credible conflicting evidence and examines why studies differ.

  5. 5

    Build the synthesis

    The answer is generated from the evidence, with claims connected to sources.

  6. 6

    Show confidence

    RAGMD explains how strongly the body of evidence supports the conclusion.

Progressive depth

10 seconds, 1 minute, or 5 minutes

Scan what you need now — drill into studies, comparisons, and sources when you have more time.

10 seconds

Bottom line + Evidence Confidence

The clinical takeaway and how strongly the evidence supports it.

1 minute

Benefits, risks, conflicts, limitations

Structured sections for a quick clinical read.

5 minutes+

Strongest studies, expert perspectives, full sources

Deep comparison, teaching, and source verification when you need more.

Example

See an evidence-weighted answer

Does testosterone replacement increase cardiovascular risk?

Product demonstration

Bottom line

For appropriately selected hypogonadal men, current higher-quality evidence does not support a blanket increase in major cardiovascular events from testosterone replacement. Risk still depends on indication, formulation, monitoring, and baseline cardiovascular status. [1–3]

Evidence confidence

High

Multiple high-quality studies directly address this question, with generally consistent findings.

Clinical takeaway

Large randomized trials and contemporary syntheses do not consistently show excess major adverse cardiac events in appropriately indicated hypogonadal men on monitored testosterone therapy.

Important conflicting evidence

Older observational cohorts raised cardiovascular concern, but design limitations and treatment-selection bias limit how directly those signals apply to current practice.

What this evidence does not establish

Optimal monitoring thresholds, patient selection in high-risk cardiovascular disease, and long-term outcomes beyond trial follow-up remain active clinical judgment areas.

Strongest evidence

Landmark RCT

Representative pivotal study from the evidence base

Large randomized trials and contemporary syntheses do not consistently show excess major adverse cardiac events in appropriately indicated hypogonadal men on monitored testosterone therapy.

Trust

Every conclusion has a trail.

Inspect the studies behind the answer. RAGMD links research evidence to its published source, including PubMed identifiers when available.

Ready to ask with confidence?

RAGMD Pro from $99/month after a 7-day free trial. Cancel anytime.